ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Rapid Diagnostic Testing for Influenza - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: October 2024
|
Report Code: QYRE-Auto-8X5991
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Rapid Diagnostic Testing for Influenza Market Size Status and Forecast 2021 2027
BUY CHAPTERS

Rapid Diagnostic Testing for Influenza - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-8X5991
Report
October 2024
Pages:128
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
BD
Abbot (Alere)
Quidel
Roche
Thermo Fisher Scientific
Meridian Bioscience
Analytik Jena
Princeton BioMeditech Corporation
Biomerieux
Sekisui Diagnostics
Response Biomedical
SA Scientific
DiaSorin (Focus Diagnostics)
Wondfo
Beijing Wantai Biological Pharmacy

Rapid Diagnostic Testing for Influenza - Market Size

The global market for Rapid Diagnostic Testing for Influenza was estimated to be worth US$ 1269 million in 2023 and is forecast to a readjusted size of US$ 1578.1 million by 2030 with a CAGR of 3.1% during the forecast period 2024-2030

Rapid Diagnostic Testing for Influenza - Market

Rapid Diagnostic Testing for Influenza - Market

Rapid influenza diagnostic tests (RIDTs) are immunoassays that can identify the presence of influenza A and B viral nucleoprotein antigens in respiratory specimens, and display the result in a qualitative way (positive vs. negative). In the United States, a number of RIDTs are commercially available. The reference standards for laboratory confirmation of influenza virus infection in respiratory specimens are reverse transcription-polymerase chain reaction (RT-PCR) or viral culture. RIDTs can yield results in a clinically relevant time frame, i.e., less than approximately 15 minutes. However, RIDTs have limited sensitivity to detect influenza viruses in respiratory specimens compared to RT-PCR or viral culture and negative RIDT test results should be interpreted with caution given the potential for false negative results, especially during peak influenza activity in a community. Some RIDTs use analyzer reader devices to standardize result interpretation.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Rapid Diagnostic Testing for Influenza, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Rapid Diagnostic Testing for Influenza by region & country, by Type, and by Application.
The Rapid Diagnostic Testing for Influenza market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rapid Diagnostic Testing for Influenza.
Market Segmentation

Scope of Rapid Diagnostic Testing for Influenza - Market Report

Report Metric Details
Report Name Rapid Diagnostic Testing for Influenza - Market
Forecasted market size in 2030 US$ 1578.1 million
CAGR 3.1%
Forecasted years 2024 - 2030
Segment by Type:
  • Digital RIDTs
  • Conventional RIDT
Segment by Application
  • Hospitals
  • POCT
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company BD, Abbot (Alere), Quidel, Roche, Thermo Fisher Scientific, Meridian Bioscience, Analytik Jena, Princeton BioMeditech Corporation, BioMerieux, Sekisui Diagnostics, Response Biomedical, SA Scientific, DiaSorin (Focus Diagnostics), Wondfo, Beijing Wantai Biological Pharmacy
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Rapid Diagnostic Testing for Influenza manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Revenue of Rapid Diagnostic Testing for Influenza in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Revenue of Rapid Diagnostic Testing for Influenza in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Rapid Diagnostic Testing for Influenza - Market size in 2030?

Ans: The Rapid Diagnostic Testing for Influenza - Market size in 2030 will be US$ 1578.1 million.

Who are the main players in the Rapid Diagnostic Testing for Influenza - Market report?

Ans: The main players in the Rapid Diagnostic Testing for Influenza - Market are BD, Abbot (Alere), Quidel, Roche, Thermo Fisher Scientific, Meridian Bioscience, Analytik Jena, Princeton BioMeditech Corporation, BioMerieux, Sekisui Diagnostics, Response Biomedical, SA Scientific, DiaSorin (Focus Diagnostics), Wondfo, Beijing Wantai Biological Pharmacy

What are the Application segmentation covered in the Rapid Diagnostic Testing for Influenza - Market report?

Ans: The Applications covered in the Rapid Diagnostic Testing for Influenza - Market report are Hospitals, POCT, Others

What are the Type segmentation covered in the Rapid Diagnostic Testing for Influenza - Market report?

Ans: The Types covered in the Rapid Diagnostic Testing for Influenza - Market report are Digital RIDTs, Conventional RIDT

1 Market Overview
1.1 Rapid Diagnostic Testing for Influenza Product Introduction
1.2 Global Rapid Diagnostic Testing for Influenza Market Size Forecast
1.3 Rapid Diagnostic Testing for Influenza Market Trends & Drivers
1.3.1 Rapid Diagnostic Testing for Influenza Industry Trends
1.3.2 Rapid Diagnostic Testing for Influenza Market Drivers & Opportunity
1.3.3 Rapid Diagnostic Testing for Influenza Market Challenges
1.3.4 Rapid Diagnostic Testing for Influenza Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Rapid Diagnostic Testing for Influenza Players Revenue Ranking (2023)
2.2 Global Rapid Diagnostic Testing for Influenza Revenue by Company (2019-2024)
2.3 Key Companies Rapid Diagnostic Testing for Influenza Manufacturing Base Distribution and Headquarters
2.4 Key Companies Rapid Diagnostic Testing for Influenza Product Offered
2.5 Key Companies Time to Begin Mass Production of Rapid Diagnostic Testing for Influenza
2.6 Rapid Diagnostic Testing for Influenza Market Competitive Analysis
2.6.1 Rapid Diagnostic Testing for Influenza Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Rapid Diagnostic Testing for Influenza Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rapid Diagnostic Testing for Influenza as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Digital RIDTs
3.1.2 Conventional RIDT
3.2 Global Rapid Diagnostic Testing for Influenza Sales Value by Type
3.2.1 Global Rapid Diagnostic Testing for Influenza Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Rapid Diagnostic Testing for Influenza Sales Value, by Type (2019-2030)
3.2.3 Global Rapid Diagnostic Testing for Influenza Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 POCT
4.1.3 Others
4.2 Global Rapid Diagnostic Testing for Influenza Sales Value by Application
4.2.1 Global Rapid Diagnostic Testing for Influenza Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Rapid Diagnostic Testing for Influenza Sales Value, by Application (2019-2030)
4.2.3 Global Rapid Diagnostic Testing for Influenza Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Rapid Diagnostic Testing for Influenza Sales Value by Region
5.1.1 Global Rapid Diagnostic Testing for Influenza Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Rapid Diagnostic Testing for Influenza Sales Value by Region (2019-2024)
5.1.3 Global Rapid Diagnostic Testing for Influenza Sales Value by Region (2025-2030)
5.1.4 Global Rapid Diagnostic Testing for Influenza Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Rapid Diagnostic Testing for Influenza Sales Value, 2019-2030
5.2.2 North America Rapid Diagnostic Testing for Influenza Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Rapid Diagnostic Testing for Influenza Sales Value, 2019-2030
5.3.2 Europe Rapid Diagnostic Testing for Influenza Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Rapid Diagnostic Testing for Influenza Sales Value, 2019-2030
5.4.2 Asia Pacific Rapid Diagnostic Testing for Influenza Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Rapid Diagnostic Testing for Influenza Sales Value, 2019-2030
5.5.2 South America Rapid Diagnostic Testing for Influenza Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Rapid Diagnostic Testing for Influenza Sales Value, 2019-2030
5.6.2 Middle East & Africa Rapid Diagnostic Testing for Influenza Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Rapid Diagnostic Testing for Influenza Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Rapid Diagnostic Testing for Influenza Sales Value
6.3 United States
6.3.1 United States Rapid Diagnostic Testing for Influenza Sales Value, 2019-2030
6.3.2 United States Rapid Diagnostic Testing for Influenza Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Rapid Diagnostic Testing for Influenza Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Rapid Diagnostic Testing for Influenza Sales Value, 2019-2030
6.4.2 Europe Rapid Diagnostic Testing for Influenza Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Rapid Diagnostic Testing for Influenza Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Rapid Diagnostic Testing for Influenza Sales Value, 2019-2030
6.5.2 China Rapid Diagnostic Testing for Influenza Sales Value by Type (%), 2023 VS 2030
6.5.3 China Rapid Diagnostic Testing for Influenza Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Rapid Diagnostic Testing for Influenza Sales Value, 2019-2030
6.6.2 Japan Rapid Diagnostic Testing for Influenza Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Rapid Diagnostic Testing for Influenza Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Rapid Diagnostic Testing for Influenza Sales Value, 2019-2030
6.7.2 South Korea Rapid Diagnostic Testing for Influenza Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Rapid Diagnostic Testing for Influenza Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Rapid Diagnostic Testing for Influenza Sales Value, 2019-2030
6.8.2 Southeast Asia Rapid Diagnostic Testing for Influenza Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Rapid Diagnostic Testing for Influenza Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Rapid Diagnostic Testing for Influenza Sales Value, 2019-2030
6.9.2 India Rapid Diagnostic Testing for Influenza Sales Value by Type (%), 2023 VS 2030
6.9.3 India Rapid Diagnostic Testing for Influenza Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 BD
7.1.1 BD Profile
7.1.2 BD Main Business
7.1.3 BD Rapid Diagnostic Testing for Influenza Products, Services and Solutions
7.1.4 BD Rapid Diagnostic Testing for Influenza Revenue (US$ Million) & (2019-2024)
7.1.5 BD Recent Developments
7.2 Abbot (Alere)
7.2.1 Abbot (Alere) Profile
7.2.2 Abbot (Alere) Main Business
7.2.3 Abbot (Alere) Rapid Diagnostic Testing for Influenza Products, Services and Solutions
7.2.4 Abbot (Alere) Rapid Diagnostic Testing for Influenza Revenue (US$ Million) & (2019-2024)
7.2.5 Abbot (Alere) Recent Developments
7.3 Quidel
7.3.1 Quidel Profile
7.3.2 Quidel Main Business
7.3.3 Quidel Rapid Diagnostic Testing for Influenza Products, Services and Solutions
7.3.4 Quidel Rapid Diagnostic Testing for Influenza Revenue (US$ Million) & (2019-2024)
7.3.5 Roche Recent Developments
7.4 Roche
7.4.1 Roche Profile
7.4.2 Roche Main Business
7.4.3 Roche Rapid Diagnostic Testing for Influenza Products, Services and Solutions
7.4.4 Roche Rapid Diagnostic Testing for Influenza Revenue (US$ Million) & (2019-2024)
7.4.5 Roche Recent Developments
7.5 Thermo Fisher Scientific
7.5.1 Thermo Fisher Scientific Profile
7.5.2 Thermo Fisher Scientific Main Business
7.5.3 Thermo Fisher Scientific Rapid Diagnostic Testing for Influenza Products, Services and Solutions
7.5.4 Thermo Fisher Scientific Rapid Diagnostic Testing for Influenza Revenue (US$ Million) & (2019-2024)
7.5.5 Thermo Fisher Scientific Recent Developments
7.6 Meridian Bioscience
7.6.1 Meridian Bioscience Profile
7.6.2 Meridian Bioscience Main Business
7.6.3 Meridian Bioscience Rapid Diagnostic Testing for Influenza Products, Services and Solutions
7.6.4 Meridian Bioscience Rapid Diagnostic Testing for Influenza Revenue (US$ Million) & (2019-2024)
7.6.5 Meridian Bioscience Recent Developments
7.7 Analytik Jena
7.7.1 Analytik Jena Profile
7.7.2 Analytik Jena Main Business
7.7.3 Analytik Jena Rapid Diagnostic Testing for Influenza Products, Services and Solutions
7.7.4 Analytik Jena Rapid Diagnostic Testing for Influenza Revenue (US$ Million) & (2019-2024)
7.7.5 Analytik Jena Recent Developments
7.8 Princeton BioMeditech Corporation
7.8.1 Princeton BioMeditech Corporation Profile
7.8.2 Princeton BioMeditech Corporation Main Business
7.8.3 Princeton BioMeditech Corporation Rapid Diagnostic Testing for Influenza Products, Services and Solutions
7.8.4 Princeton BioMeditech Corporation Rapid Diagnostic Testing for Influenza Revenue (US$ Million) & (2019-2024)
7.8.5 Princeton BioMeditech Corporation Recent Developments
7.9 BioMerieux
7.9.1 BioMerieux Profile
7.9.2 BioMerieux Main Business
7.9.3 BioMerieux Rapid Diagnostic Testing for Influenza Products, Services and Solutions
7.9.4 BioMerieux Rapid Diagnostic Testing for Influenza Revenue (US$ Million) & (2019-2024)
7.9.5 BioMerieux Recent Developments
7.10 Sekisui Diagnostics
7.10.1 Sekisui Diagnostics Profile
7.10.2 Sekisui Diagnostics Main Business
7.10.3 Sekisui Diagnostics Rapid Diagnostic Testing for Influenza Products, Services and Solutions
7.10.4 Sekisui Diagnostics Rapid Diagnostic Testing for Influenza Revenue (US$ Million) & (2019-2024)
7.10.5 Sekisui Diagnostics Recent Developments
7.11 Response Biomedical
7.11.1 Response Biomedical Profile
7.11.2 Response Biomedical Main Business
7.11.3 Response Biomedical Rapid Diagnostic Testing for Influenza Products, Services and Solutions
7.11.4 Response Biomedical Rapid Diagnostic Testing for Influenza Revenue (US$ Million) & (2019-2024)
7.11.5 Response Biomedical Recent Developments
7.12 SA Scientific
7.12.1 SA Scientific Profile
7.12.2 SA Scientific Main Business
7.12.3 SA Scientific Rapid Diagnostic Testing for Influenza Products, Services and Solutions
7.12.4 SA Scientific Rapid Diagnostic Testing for Influenza Revenue (US$ Million) & (2019-2024)
7.12.5 SA Scientific Recent Developments
7.13 DiaSorin (Focus Diagnostics)
7.13.1 DiaSorin (Focus Diagnostics) Profile
7.13.2 DiaSorin (Focus Diagnostics) Main Business
7.13.3 DiaSorin (Focus Diagnostics) Rapid Diagnostic Testing for Influenza Products, Services and Solutions
7.13.4 DiaSorin (Focus Diagnostics) Rapid Diagnostic Testing for Influenza Revenue (US$ Million) & (2019-2024)
7.13.5 DiaSorin (Focus Diagnostics) Recent Developments
7.14 Wondfo
7.14.1 Wondfo Profile
7.14.2 Wondfo Main Business
7.14.3 Wondfo Rapid Diagnostic Testing for Influenza Products, Services and Solutions
7.14.4 Wondfo Rapid Diagnostic Testing for Influenza Revenue (US$ Million) & (2019-2024)
7.14.5 Wondfo Recent Developments
7.15 Beijing Wantai Biological Pharmacy
7.15.1 Beijing Wantai Biological Pharmacy Profile
7.15.2 Beijing Wantai Biological Pharmacy Main Business
7.15.3 Beijing Wantai Biological Pharmacy Rapid Diagnostic Testing for Influenza Products, Services and Solutions
7.15.4 Beijing Wantai Biological Pharmacy Rapid Diagnostic Testing for Influenza Revenue (US$ Million) & (2019-2024)
7.15.5 Beijing Wantai Biological Pharmacy Recent Developments
8 Industry Chain Analysis
8.1 Rapid Diagnostic Testing for Influenza Industrial Chain
8.2 Rapid Diagnostic Testing for Influenza Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Rapid Diagnostic Testing for Influenza Sales Model
8.5.2 Sales Channel
8.5.3 Rapid Diagnostic Testing for Influenza Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
FEATURED COMPANIES
BD
Abbot (Alere)
Quidel
Roche
Thermo Fisher Scientific
Meridian Bioscience
Analytik Jena
Princeton BioMeditech Corporation
Biomerieux
Sekisui Diagnostics
Response Biomedical
SA Scientific
DiaSorin (Focus Diagnostics)
Wondfo
Beijing Wantai Biological Pharmacy
List of Tables
    Table 1. Rapid Diagnostic Testing for Influenza Market Trends
    Table 2. Rapid Diagnostic Testing for Influenza Market Drivers & Opportunity
    Table 3. Rapid Diagnostic Testing for Influenza Market Challenges
    Table 4. Rapid Diagnostic Testing for Influenza Market Restraints
    Table 5. Global Rapid Diagnostic Testing for Influenza Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Rapid Diagnostic Testing for Influenza Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Rapid Diagnostic Testing for Influenza Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Rapid Diagnostic Testing for Influenza Product Type
    Table 9. Key Companies Time to Begin Mass Production of Rapid Diagnostic Testing for Influenza
    Table 10. Global Rapid Diagnostic Testing for Influenza Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rapid Diagnostic Testing for Influenza as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Rapid Diagnostic Testing for Influenza Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Rapid Diagnostic Testing for Influenza Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Rapid Diagnostic Testing for Influenza Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Rapid Diagnostic Testing for Influenza Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Rapid Diagnostic Testing for Influenza Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Rapid Diagnostic Testing for Influenza Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Rapid Diagnostic Testing for Influenza Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Rapid Diagnostic Testing for Influenza Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Rapid Diagnostic Testing for Influenza Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Rapid Diagnostic Testing for Influenza Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Rapid Diagnostic Testing for Influenza Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Rapid Diagnostic Testing for Influenza Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Rapid Diagnostic Testing for Influenza Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Rapid Diagnostic Testing for Influenza Sales Value by Region (2019-2024) & (%)
    Table 27. Global Rapid Diagnostic Testing for Influenza Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Rapid Diagnostic Testing for Influenza Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Rapid Diagnostic Testing for Influenza Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Rapid Diagnostic Testing for Influenza Sales Value, (2025-2030) & (US$ Million)
    Table 31. BD Basic Information List
    Table 32. BD Description and Business Overview
    Table 33. BD Rapid Diagnostic Testing for Influenza Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Rapid Diagnostic Testing for Influenza Business of BD (2019-2024)
    Table 35. BD Recent Developments
    Table 36. Abbot (Alere) Basic Information List
    Table 37. Abbot (Alere) Description and Business Overview
    Table 38. Abbot (Alere) Rapid Diagnostic Testing for Influenza Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Rapid Diagnostic Testing for Influenza Business of Abbot (Alere) (2019-2024)
    Table 40. Abbot (Alere) Recent Developments
    Table 41. Quidel Basic Information List
    Table 42. Quidel Description and Business Overview
    Table 43. Quidel Rapid Diagnostic Testing for Influenza Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Rapid Diagnostic Testing for Influenza Business of Quidel (2019-2024)
    Table 45. Quidel Recent Developments
    Table 46. Roche Basic Information List
    Table 47. Roche Description and Business Overview
    Table 48. Roche Rapid Diagnostic Testing for Influenza Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Rapid Diagnostic Testing for Influenza Business of Roche (2019-2024)
    Table 50. Roche Recent Developments
    Table 51. Thermo Fisher Scientific Basic Information List
    Table 52. Thermo Fisher Scientific Description and Business Overview
    Table 53. Thermo Fisher Scientific Rapid Diagnostic Testing for Influenza Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Rapid Diagnostic Testing for Influenza Business of Thermo Fisher Scientific (2019-2024)
    Table 55. Thermo Fisher Scientific Recent Developments
    Table 56. Meridian Bioscience Basic Information List
    Table 57. Meridian Bioscience Description and Business Overview
    Table 58. Meridian Bioscience Rapid Diagnostic Testing for Influenza Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Rapid Diagnostic Testing for Influenza Business of Meridian Bioscience (2019-2024)
    Table 60. Meridian Bioscience Recent Developments
    Table 61. Analytik Jena Basic Information List
    Table 62. Analytik Jena Description and Business Overview
    Table 63. Analytik Jena Rapid Diagnostic Testing for Influenza Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Rapid Diagnostic Testing for Influenza Business of Analytik Jena (2019-2024)
    Table 65. Analytik Jena Recent Developments
    Table 66. Princeton BioMeditech Corporation Basic Information List
    Table 67. Princeton BioMeditech Corporation Description and Business Overview
    Table 68. Princeton BioMeditech Corporation Rapid Diagnostic Testing for Influenza Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Rapid Diagnostic Testing for Influenza Business of Princeton BioMeditech Corporation (2019-2024)
    Table 70. Princeton BioMeditech Corporation Recent Developments
    Table 71. BioMerieux Basic Information List
    Table 72. BioMerieux Description and Business Overview
    Table 73. BioMerieux Rapid Diagnostic Testing for Influenza Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Rapid Diagnostic Testing for Influenza Business of BioMerieux (2019-2024)
    Table 75. BioMerieux Recent Developments
    Table 76. Sekisui Diagnostics Basic Information List
    Table 77. Sekisui Diagnostics Description and Business Overview
    Table 78. Sekisui Diagnostics Rapid Diagnostic Testing for Influenza Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Rapid Diagnostic Testing for Influenza Business of Sekisui Diagnostics (2019-2024)
    Table 80. Sekisui Diagnostics Recent Developments
    Table 81. Response Biomedical Basic Information List
    Table 82. Response Biomedical Description and Business Overview
    Table 83. Response Biomedical Rapid Diagnostic Testing for Influenza Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Rapid Diagnostic Testing for Influenza Business of Response Biomedical (2019-2024)
    Table 85. Response Biomedical Recent Developments
    Table 86. SA Scientific Basic Information List
    Table 87. SA Scientific Description and Business Overview
    Table 88. SA Scientific Rapid Diagnostic Testing for Influenza Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Rapid Diagnostic Testing for Influenza Business of SA Scientific (2019-2024)
    Table 90. SA Scientific Recent Developments
    Table 91. DiaSorin (Focus Diagnostics) Basic Information List
    Table 92. DiaSorin (Focus Diagnostics) Description and Business Overview
    Table 93. DiaSorin (Focus Diagnostics) Rapid Diagnostic Testing for Influenza Products, Services and Solutions
    Table 94. Revenue (US$ Million) in Rapid Diagnostic Testing for Influenza Business of DiaSorin (Focus Diagnostics) (2019-2024)
    Table 95. DiaSorin (Focus Diagnostics) Recent Developments
    Table 96. Wondfo Basic Information List
    Table 97. Wondfo Description and Business Overview
    Table 98. Wondfo Rapid Diagnostic Testing for Influenza Products, Services and Solutions
    Table 99. Revenue (US$ Million) in Rapid Diagnostic Testing for Influenza Business of Wondfo (2019-2024)
    Table 100. Wondfo Recent Developments
    Table 101. Beijing Wantai Biological Pharmacy Basic Information List
    Table 102. Beijing Wantai Biological Pharmacy Description and Business Overview
    Table 103. Beijing Wantai Biological Pharmacy Rapid Diagnostic Testing for Influenza Products, Services and Solutions
    Table 104. Revenue (US$ Million) in Rapid Diagnostic Testing for Influenza Business of Beijing Wantai Biological Pharmacy (2019-2024)
    Table 105. Beijing Wantai Biological Pharmacy Recent Developments
    Table 106. Key Raw Materials Lists
    Table 107. Raw Materials Key Suppliers Lists
    Table 108. Rapid Diagnostic Testing for Influenza Downstream Customers
    Table 109. Rapid Diagnostic Testing for Influenza Distributors List
    Table 110. Research Programs/Design for This Report
    Table 111. Key Data Information from Secondary Sources
    Table 112. Key Data Information from Primary Sources
    Table 113. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Rapid Diagnostic Testing for Influenza Product Picture
    Figure 2. Global Rapid Diagnostic Testing for Influenza Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Rapid Diagnostic Testing for Influenza Sales Value (2019-2030) & (US$ Million)
    Figure 4. Rapid Diagnostic Testing for Influenza Report Years Considered
    Figure 5. Global Rapid Diagnostic Testing for Influenza Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Rapid Diagnostic Testing for Influenza Revenue in 2023
    Figure 7. Rapid Diagnostic Testing for Influenza Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Digital RIDTs Picture
    Figure 9. Conventional RIDT Picture
    Figure 10. Global Rapid Diagnostic Testing for Influenza Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 11. Global Rapid Diagnostic Testing for Influenza Sales Value Market Share by Type, 2023 & 2030
    Figure 12. Product Picture of Hospitals
    Figure 13. Product Picture of POCT
    Figure 14. Product Picture of Others
    Figure 15. Global Rapid Diagnostic Testing for Influenza Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 16. Global Rapid Diagnostic Testing for Influenza Sales Value Market Share by Application, 2023 & 2030
    Figure 17. North America Rapid Diagnostic Testing for Influenza Sales Value (2019-2030) & (US$ Million)
    Figure 18. North America Rapid Diagnostic Testing for Influenza Sales Value by Country (%), 2023 VS 2030
    Figure 19. Europe Rapid Diagnostic Testing for Influenza Sales Value (2019-2030) & (US$ Million)
    Figure 20. Europe Rapid Diagnostic Testing for Influenza Sales Value by Country (%), 2023 VS 2030
    Figure 21. Asia Pacific Rapid Diagnostic Testing for Influenza Sales Value (2019-2030) & (US$ Million)
    Figure 22. Asia Pacific Rapid Diagnostic Testing for Influenza Sales Value by Country (%), 2023 VS 2030
    Figure 23. South America Rapid Diagnostic Testing for Influenza Sales Value (2019-2030) & (US$ Million)
    Figure 24. South America Rapid Diagnostic Testing for Influenza Sales Value by Country (%), 2023 VS 2030
    Figure 25. Middle East & Africa Rapid Diagnostic Testing for Influenza Sales Value (2019-2030) & (US$ Million)
    Figure 26. Middle East & Africa Rapid Diagnostic Testing for Influenza Sales Value by Country (%), 2023 VS 2030
    Figure 27. Key Countries/Regions Rapid Diagnostic Testing for Influenza Sales Value (%), (2019-2030)
    Figure 28. United States Rapid Diagnostic Testing for Influenza Sales Value, (2019-2030) & (US$ Million)
    Figure 29. United States Rapid Diagnostic Testing for Influenza Sales Value by Type (%), 2023 VS 2030
    Figure 30. United States Rapid Diagnostic Testing for Influenza Sales Value by Application (%), 2023 VS 2030
    Figure 31. Europe Rapid Diagnostic Testing for Influenza Sales Value, (2019-2030) & (US$ Million)
    Figure 32. Europe Rapid Diagnostic Testing for Influenza Sales Value by Type (%), 2023 VS 2030
    Figure 33. Europe Rapid Diagnostic Testing for Influenza Sales Value by Application (%), 2023 VS 2030
    Figure 34. China Rapid Diagnostic Testing for Influenza Sales Value, (2019-2030) & (US$ Million)
    Figure 35. China Rapid Diagnostic Testing for Influenza Sales Value by Type (%), 2023 VS 2030
    Figure 36. China Rapid Diagnostic Testing for Influenza Sales Value by Application (%), 2023 VS 2030
    Figure 37. Japan Rapid Diagnostic Testing for Influenza Sales Value, (2019-2030) & (US$ Million)
    Figure 38. Japan Rapid Diagnostic Testing for Influenza Sales Value by Type (%), 2023 VS 2030
    Figure 39. Japan Rapid Diagnostic Testing for Influenza Sales Value by Application (%), 2023 VS 2030
    Figure 40. South Korea Rapid Diagnostic Testing for Influenza Sales Value, (2019-2030) & (US$ Million)
    Figure 41. South Korea Rapid Diagnostic Testing for Influenza Sales Value by Type (%), 2023 VS 2030
    Figure 42. South Korea Rapid Diagnostic Testing for Influenza Sales Value by Application (%), 2023 VS 2030
    Figure 43. Southeast Asia Rapid Diagnostic Testing for Influenza Sales Value, (2019-2030) & (US$ Million)
    Figure 44. Southeast Asia Rapid Diagnostic Testing for Influenza Sales Value by Type (%), 2023 VS 2030
    Figure 45. Southeast Asia Rapid Diagnostic Testing for Influenza Sales Value by Application (%), 2023 VS 2030
    Figure 46. India Rapid Diagnostic Testing for Influenza Sales Value, (2019-2030) & (US$ Million)
    Figure 47. India Rapid Diagnostic Testing for Influenza Sales Value by Type (%), 2023 VS 2030
    Figure 48. India Rapid Diagnostic Testing for Influenza Sales Value by Application (%), 2023 VS 2030
    Figure 49. Rapid Diagnostic Testing for Influenza Industrial Chain
    Figure 50. Rapid Diagnostic Testing for Influenza Manufacturing Cost Structure
    Figure 51. Channels of Distribution (Direct Sales, and Distribution)
    Figure 52. Bottom-up and Top-down Approaches for This Report
    Figure 53. Data Triangulation
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Quinolones Residue Detection Service - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-21P14799
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Quinolones Detection Kit - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-38P14534
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Global Tetanus toxin Inhibitors Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-27W18368
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Latent Tuberculosis Infection Screening Test - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-9U15029
Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions